Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Momenta Pharmaceuticals launches phase II/III study of nipocalimab in wAIHA

Aug. 2, 2019

FDA approves Accrufer for iron deficiency in adults

July 29, 2019

First-generation PI3KC2alpha inhibitors as promising antithrombotic agents

July 23, 2019

Discovery and preclinical identification of novel NOX1-selective inhibitor, 2APT-PD06

July 23, 2019

Achillion presents promising data from phase I MAD study of ACH-5228

July 23, 2019

Mimicking bone marrow keeps cultured blood stem cells quiescent

July 18, 2019

Finding MDS' iron fist

July 17, 2019

Activity maintained for recombinant factor VIII modified to extend half-life: MG-1121

July 16, 2019

Bodyweight-adjusted rivaroxaban treatment in children with acute venous thromboembolism

July 15, 2019

New CRISPR/Cas9 transgenic mice with mutated F8 gene as a model for the study of hemophilia A

July 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.